SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-24-053407
Filing Date
2024-06-17
Accepted
2024-06-17 17:22:46
Documents
90
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0207963-6k_neurose.htm   iXBRL 6-K 16745
2 CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2023 ea020796301ex99-1_neurose.htm   iXBRL EX-99.1 658037
3 OPERATING AND FINANCIAL REVIEW AND PROSPECTS AS OF DECEMBER 31, 2023 ea020796301ex99-2_neurose.htm EX-99.2 212708
4 CONSENT OF INDEPENDENT REGISTERED ACCOUNTING FIRM ea020796301ex99-3_neurose.htm EX-99.3 2004
  Complete submission text file 0001213900-24-053407.txt   5840232

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE nrsn-20231231.xsd EX-101.SCH 76763
6 XBRL CALCULATION FILE nrsn-20231231_cal.xml EX-101.CAL 36417
7 XBRL DEFINITION FILE nrsn-20231231_def.xml EX-101.DEF 290018
8 XBRL LABEL FILE nrsn-20231231_lab.xml EX-101.LAB 557125
9 XBRL PRESENTATION FILE nrsn-20231231_pre.xml EX-101.PRE 297595
94 EXTRACTED XBRL INSTANCE DOCUMENT ea0207963-6k_neurose_htm.xml XML 732189
Mailing Address 11 HAMENOFIM ST. BUILDING B HERZLIYA L3 4672562
Business Address 11 HAMENOFIM ST. BUILDING B HERZLIYA L3 4672562 972-9-9531142
NeuroSense Therapeutics Ltd. (Filer) CIK: 0001875091 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-41084 | Film No.: 241049356
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)